August 2010- Volume 6, Issue 8
August 2010
In this Issue
Omics & Systems Biology
Pushing the limits of phosphoproteomics
Pushing the limits of phosphoproteomics
Purdue University researcher patents new retrieval method that makes studying cancer proteins easier
Ariadne’s thread of connections
Ariadne’s thread of connections
Bioinformatics company to collaborate in multimillion-dollar EU-based neuromuscular disease consortium to find biomarkers
Boosting R&D with a little M&A
Boosting R&D with a little M&A
Gilead Sciences acquires CGI Pharmaceuticals and adds numerous small- molecule kinase inhibitor compounds to its pipeline
A class of their own
A class of their own
Santaris Pharma, miRagen Therapeutics to develop microRNAs for treatment of cardiovascular disease
Multimillion miRNA deal
Multimillion miRNA deal
sanofi-aventis, Regulus form strategic alliance in microRNA therapeutics
Special Reports
Let’s work together
Let’s work together
Peeling back the layers of integrated approaches to oncology research
The big picture
The big picture
Multiple approaches—and ultimately, more comprehensive ones—are critical to understanding and treating cancer
New Products
Automates preparation of fragment libraries
Automates preparation of fragment libraries
Beckman Coulter Genomics has introduced the SPRIworks Fragment Library System II.
Research & Development
Getting under their skin
Getting under their skin
Valeant and Biovail agree to merge, creating leader in dermatology and neurology pharmaceuticals
sanofi-aventis continues R&D spending spree
sanofi-aventis continues R&D spending spree
French pharma acquires U.S. biopharmaceutical firm TargeGen for $75 million
Lilly acquisition blossoms
Lilly acquisition blossoms
Company to pay as much as $380 million for Alnara
Fail-safe product and deal
Fail-safe product and deal
Option agreement between Cadence Pharmaceuticals and Incline Therapeutics gives Cadence two option periods to acquire Incline
Celgene reaches into deep pockets again
Celgene reaches into deep pockets again
Enticed by tumor drug, Celgene acquires Abraxis BioScience for nearly $3 billion upfront and up to $650 million if certain goals are met
Diagnostics
TRANSCENDing a typical partnership
TRANSCENDing a typical partnership
MIT’s Koch Institute collaborates with Ortho-McNeil-Janssen and affiliates in oncology R&D
A personal touch for cancer therapy
A personal touch for cancer therapy
Aeterna Zentaris to collaborate with Almac on therapy and companion diagnostic in multiple oncology targets
Signed on the dotted line
Signed on the dotted line
Signature Diagnostics to use Affymetrix microarray technology for detecting and predicting progression of colorectal cancer
Rheumatoid arthritis reprise
Rheumatoid arthritis reprise
TcLand Expression, a spinoff of Inserm Transfert, rejoins former partner to pursue RA companion diagnostics
Global News
A pain-free alliance
A pain-free alliance
Servier and Galapagos initiate strategic alliance in osteoarthritis
That’s Italian
That’s Italian
Aptuit to acquire operations at GSK’s Medicines Research Centre in Verona
The potential of Polish science
The potential of Polish science
Selvita and Orion collaborate on Alzheimer’s disease program
From the Buckeye State to Beijing
From the Buckeye State to Beijing
BioOhio, Beijing Pharma forge international biomedical, business partnership
Instruments & Informatics
Sosei to acquire Activus Pharma
Sosei to acquire Activus Pharma
Deal marks Sosei’s continued efforts to grow through non-organic means
Picking up the slack … and then some
Picking up the slack … and then some
Eurofins MWG Operon and Genomatix join forces to offer advanced NGS
Getting a signal
Getting a signal
Promega, SignalChem to offer complete kinase solutions
Human genomics for the masses
Human genomics for the masses
Roche and IBM collaborate on nanopore-based DNA sequencing technology with eyes toward advancing personalized healthcare
Commentary
The role of nanoemulsions in vaccines, adjuvants, anti-infectives and dermatological treatments
The role of nanoemulsions in vaccines, adjuvants, anti-infectives and dermatological treatments
The pharmaceutical industry continues to struggle with bringing new, commercially viable therapies to market.
Where will innovation come from?
Where will innovation come from?
In the early 1980s, I traveled to Berlin and to China for the first time. To reach Berlin, you flew in a PanAm DC-9 from Frankfurt, your only choice of airline and departure airport. It was a beautiful day. Crossing the border to East Germany, many things disappeared: color, highways, modern buildings and traffic. From low altitudes, it appeared that 30 to 40 years had just been lost.
Editor's Focus
ddn dissects current cancer craze
ddn dissects current cancer craze
Business deals and agreements associated with cancer research are plentiful these days, and this month, ddn’s editors and writers give you several examples of the latest oncology-related acquisitions, mergers and partnerships to be signed in this burgeoning area of pharmaceutical and biological research.
Contract Services
Back to the future with Parkinson’s research
Back to the future with Parkinson’s research
Michael J. Fox Foundation partners with leading CROs to develop biomarker candidates for Parkinson’s disease
Changing the channel
Changing the channel
Milestone-driver collaboration between Essen BioScience and Nycomed boosts ion-channel drug discovery
A gem of a partnership
A gem of a partnership
Emerald BioStructures, FORMA Therapeutics partner to develop treatments for lymphoma and other cancers
Going for prime time
Going for prime time
Quintiles inks deal with University Malaya Medical Center in Malaysia
